Drugs / XZP-3621
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05836805 | May → Aug 2023 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05034120 | Dec 2021 → Mar 2022 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05055232 | Mar 2019 → Aug 2023 | non-small cell lung carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05482087 | Sep 2022 → May 2025 | non-small cell lung carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05204628 | Feb 2022 → May 2025 | non-small cell lung carcinoma | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZP-3621 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05836805 ↗ |
| Action | Inhibit | “novel ALK inhibitor” PMID 41539180 ↗ Jan 2026 |
| Route | Oral | “single oral dose of XZP-3621” NCT05034120 ↗ |
| Target | ALK | “novel ALK inhibitor” PMID 41539180 ↗ Jan 2026 |